Minerva Neurosciences, Inc: Minerva Neurosciences Provides U

Minerva Neurosciences, Inc: Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Company to Host Webcast Wednesday, April 13, 2022 at 11am ETWALTHAM, Mass., April 07, 2022(NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system

Related Keywords

Miami , Florida , United States , Leucht , Baden Wüberg , Germany , Helen Shik , Phil Harvey , Leonardm Miller , Minerva Neurosciences , Billy Dunn , Remy Luthringer , Tiffany Farchione , Frederick Ahlholm , Drug Administration , Nasdaq , Office Of Neuroscience , University Of Miami Miller School Medicine , Shik Communications , Minerva Neurosciences Inc , Behavioral Sciences , Division Of Psychiatry , Company To Host Webcast , Host Webcast Wednesday , Executive Chairman , Chief Executive Officer , Geoff Race , Miami Miller School , Private Securities Litigation Reform Act , Aminerva , Neurosciences , Rovides , Update , Rom , Type , Meeting , Text , Steps , Preparation , Submission , Drug , Application , Roluperidone , Treatment , Negative , Symptoms , Schizophrenia ,